Actively Recruiting
Concordance Between the Measurement of Whole Blood Fibrinogen by the qLabs®FIB Analyzer and Its Measurement by Conventional Method (Clauss Fibrinogen) in the Context of Severe Postpartum Haemorrhage
Led by Assistance Publique - Hôpitaux de Paris · Updated on 2025-09-12
70
Participants Needed
2
Research Sites
95 weeks
Total Duration
On this page
Sponsors
A
Assistance Publique - Hôpitaux de Paris
Lead Sponsor
U
URC-CIC Paris Descartes Necker Cochin
Collaborating Sponsor
AI-Summary
What this Trial Is About
In France in 2021, 11.6% of deliveries were complicated by a postpartum haemorrhage (PPH), including 3.0% by severe PPH (the bleeding volume exceeds 1000 ml). Severe PPH is the 5th cause of maternal death (8.4% or 1.2 deaths per 100,000 live births). These deaths were considered preventable in 90% of cases. A plasma fibrinogen concentration below 2 g/L is considered as a critical threshold which constitutes a marker of severity of PPH and is significantly associated with the occurrence of severe PPH. Measuring the concentration of fibrinogen using a rapid test, simple to perform and interpret, available in the delivery room could optimize the management of severe PPH. The qLabs®FIB analyzer distributed by the Stago Biocare laboratory for the rapid determination of the fibrinogen concentration at the patient's bedside could meet this objective.
CONDITIONS
Official Title
Concordance Between the Measurement of Whole Blood Fibrinogen by the qLabs®FIB Analyzer and Its Measurement by Conventional Method (Clauss Fibrinogen) in the Context of Severe Postpartum Haemorrhage
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adult patients treated for severe postpartum haemorrhage defined as bleeding greater than 1000 ml within 24 hours after delivery
- Patients informed about the study who have not opposed participation
- Delivery by any route (vaginal or caesarean)
You will not qualify if you...
- Opposition to participation in the study
- Presence of a constitutional fibrinogen deficiency
- Patients under guardianship or curatorship
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Hôpital Cochin Maternité Port Royal
Paris, France, 75014
Actively Recruiting
2
Hôpital Necker-Enfants Malades
Paris, France, 75015
Actively Recruiting
Research Team
H
Hawa KEITA-MEYER, MD-PhD
CONTACT
H
Hélène Morel
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here